A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

Exclusion Criteria

• •1. Subjects who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
• •2. Subjects who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
• •3. In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on.
• •4. Other active uncontrolled infection.
• •5. Known alcohol or drug dependence.
• •6. Subjects with mental disorders or poor compliance.
• •7. Women who are pregnant or breastfeeding.
• •8. Subjects in the opinion of the investigator are not suitable for this clinical study due to other serious systemic diseases or other reasons.